Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06747858 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
A Phase 2 study of Cystic Fibrosis and CFTR Gene Mutation, sponsored by Arcturus Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 11
- Study locations
NCT06747858 is a Phase 2 study of Cystic Fibrosis and CFTR Gene Mutation that is actively recruiting participants, run by Arcturus Therapeutics. The registered enrollment target is 12 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT06747858, a Phase 2 study of Cystic Fibrosis and CFTR Gene Mutation, is actively recruiting participants, sponsored by Arcturus Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 11
- Study locations
Study Summary
ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.
Conditions Studied
Interventions
- BIOLOGICAL ARCT-032
Study Locations (11)
Florida
- Joe DiMaggio Children's Hospital - Hollywood
- Central Florida Pulmonary Group - Orlando
Arizona
- University of Arizona - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
California
- Children's Hospital of Los Angeles - Los Angeles
Illinois
- The Cystic Fibrosis Institute - Northfield
Massachusetts
- Boston Children's Hospital - Boston
Missouri
- Washington University - St Louis
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-12-12 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06747858
The ClinicalTrials.gov registry entry for NCT06747858 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower). The listed sponsor is Arcturus Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which ARCT-032 is the first listed.
NCT06747858 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Florida, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06747858 about?
NCT06747858 is a clinical study titled "Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis". ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.
What is the current status of trial NCT06747858?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2024-12-12. Estimated completion is 2025-12.
What conditions does trial NCT06747858 study?
This clinical trial studies the following conditions: Cystic Fibrosis, CFTR Gene Mutation.
What interventions are being tested in trial NCT06747858?
The interventions under investigation include: ARCT-032 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06747858?
This trial is sponsored by Arcturus Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06747858 being conducted?
This trial has 11 study locations across Arizona, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
RECRUITING · Phase 2
-
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
RECRUITING · Phase 2
-
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
RECRUITING · Phase 2
-
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
ACTIVE NOT RECRUITING · Phase 2
-
Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.